Population pharmacokinetic modeling of cefadroxil renal transport in wild-type and Pept2 knockout mice

References

• Barbhaiya RH. (1996). A pharacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos 17:319–30
   PubMed Web of Science ®Google Scholar
• Beal SL, Sheiner LB. (1984). NONMEM users guide: users basic guide April 1980. Oakland (CA): University of California Press
   Google Scholar
• Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. (2011). Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143–51
   PubMed Web of Science ®Google Scholar
• Boll M, Herget M, Wagener M, et al. (1996). Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proc Natl Acad Sci USA 93:284–89
   PubMed Web of Science ®Google Scholar
• Buck RE, Price KE. (1977). Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 11:324–30
   PubMed Web of Science ®Google Scholar
• Courtieu AL, Drugeon H. (1983). Compared sensitivities of 532 bacterial strains to six cephalosporins. Int J Clin Pharmacol Res 3:195–201
   PubMedGoogle Scholar
• Daniel H, Kottra G. (2004). The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447:610–18
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–91
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. (2003). Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med 348:538–49
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Brandsch M, Prasad PD, et al. (1995). Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 270:25672–677
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Huang W, Wang H, et al. (1998). Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 246:470–75
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonell MC, Granero L, Torres-Molina F, et al. (1993). Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos 21:215–17
   PubMed Web of Science ®Google Scholar
• Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF. (1991). Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol 41:179–83
   PubMed Web of Science ®Google Scholar
• Hartstein AI, Patrick KE, Jones SR, et al. (1977). Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin. Antimicrob Agents Chemother 12:93–7
   PubMed Web of Science ®Google Scholar
• Hu Y, Shen H, Keep RF, Smith DE. (2007). Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103:2058–65
   PubMed Web of Science ®Google Scholar
• Huh Y, Hynes SM, Smith DE, Feng MR. (2013). Importance of peptide transporter 2 on the cerebrospinal fluid efflux kinetics of glycylsarcosine characterized by nonlinear mixed effects modeling. Pharm Res 30:1423–34
   PubMed Web of Science ®Google Scholar
• Hurtado FK, Weber B, Derendorf H, et al. (2014). Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother 58:678–86
   PubMed Web of Science ®Google Scholar
• Inui K, Tomita Y, Katsura T, et al. (1992). H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes. J Pharmacol Exp Ther 260:482–86
   PubMed Web of Science ®Google Scholar
• Jung KY, Takeda M, Shimoda M, et al. (2002). Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci 70:1861–74
   PubMed Web of Science ®Google Scholar
• Kamal MA, Keep RF, Smith DE. (2008). Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 23:236–42
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Karlsson MO, Hooker A. (2013). Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2:e50
   PubMedGoogle Scholar
• Khamdang S, Takeda M, Babu E, et al. (2003). Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 465:1–7
   PubMed Web of Science ®Google Scholar
• La Rosa F, Ripa S, Prenna M, et al. (1982). Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob Agents Chemother 21:320–22
   PubMed Web of Science ®Google Scholar
• Lindbom L, Ribbing J, Jonsson EN. (2004). Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75:85–94
   PubMed Web of Science ®Google Scholar
• Liu R, Tang AM, Tan YL, et al. (2011). Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects. Drug Metab Pharmacokinet 26:87–93
   PubMed Web of Science ®Google Scholar
• Lode H, Stahlmann R, Koeppe P. (1979). Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother 16:1–6
   PubMed Web of Science ®Google Scholar
• Marino EL, Dominguez-Gil A. (1980). Influence of dose on the pharmacokinetics of cefadroxil. Eur J Clin Pharmacol 18:505–09
   PubMed Web of Science ®Google Scholar
• Nightingale C. (1980). Pharmacokinetics of the oral cephalosporins in adults. J Int Med Res 8:2–8
   PubMed Web of Science ®Google Scholar
• Ocheltree SM, Shen H, Hu Y, et al. (2004). Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 308:462–67
   PubMed Web of Science ®Google Scholar
• Pinsonneault J, Nielsen CU, Sadee W. (2004). Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 311:1088–96
   PubMed Web of Science ®Google Scholar
• Posada MM, Smith DE. (2013). In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice. Pharm Res 30:2931–39
   PubMed Web of Science ®Google Scholar
• Ries M, Wenzel U, Daniel H. (1994). Transport of cefadroxil in rat kidney brush-border membranes is mediated by two electrogenic H+-coupled systems. J Pharmacol Exp Ther 271:1327–33
   PubMed Web of Science ®Google Scholar
• Ripa S, Prenna M. (1979). Laboratory studies with BL-S 578 (Cefadroxil) a new broad-spectrum orally active cephalosporin. Chemotherapy 25:9–13
   PubMed Web of Science ®Google Scholar
• Rodriguez L, Batlle A, Di Venosa G, et al. (2006). Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours. Int J Biochem Cell Biol 38:1530–39
   PubMed Web of Science ®Google Scholar
• Ruiz-Carretero P, Merino-Sanjuan M, Nacher A, Casabo VG. (2004). Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Eur J Pharm Sci 21:217–23
   PubMed Web of Science ®Google Scholar
• Santella PJ, Henness D. (1982). A review of the bioavailability of cefadroxil. J Antimicrob Chemother 10 Suppl B:17–25
   PubMed Web of Science ®Google Scholar
• Shen H, Keep RF, Hu Y, Smith DE. (2005). PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. J Pharmacol Exp Ther 315:1101–18
   PubMed Web of Science ®Google Scholar
• Shen H, Ocheltree SM, Hu Y, et al. (2007). Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209–16
   PubMed Web of Science ®Google Scholar
• Shen H, Smith DE, Keep RF, et al. (2003). Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J Biol Chem 278:4786–91
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. (2005). Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689–723
   PubMed Web of Science ®Google Scholar
• Smith DE, Clemencon B, Hediger MA. (2013). Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med 34:323–36
   PubMed Web of Science ®Google Scholar
• Takeda M, Babu E, Narikawa S, Endou H. (2002). Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438:137–42
   PubMed Web of Science ®Google Scholar
• Tanrisever B, Santella PJ. (1986). Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs 32 Suppl 3:1–16
   PubMed Web of Science ®Google Scholar
• Terada T, Irie M, Okuda M, Inui K. (2004). Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem Biophys Res Commun 316:416–20
   PubMed Web of Science ®Google Scholar